Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial

Chimeric Therapeutics (ASX: $CHM) has received ethics approval for the initiation of the multi-site Phase 1/2 clinical trial of CHM CDH17 in patients with advanced gastrointestinal (GI) cancers. The approval represents a significant milestone in advancing the program toward study initiation under FDA regulations.

Executive Commentary on CHM CDH17 Phase 1/2 Clinical Trial Approval

We are excited to achieve this milestone in anticipation of opening our clinical trial of CHM CDH17 for patients with advanced GI cancers; this marks a great step forward for the use of cell therapies in solid tumours.

Summary of CHM CDH17 Phase 1/2 Clinical Trial Approval

Chimeric Therapeutics (ASX: $CHM) has received ethics approval for the initiation of the multi-site Phase 1/2 clinical trial of CHM CDH17 in patients with advanced gastrointestinal (GI) cancers. The approval represents a significant milestone in advancing the program toward study initiation under FDA regulations. CHM CDH17 is a 3rd generation, novel CAR T cell therapy that targets CDH17, a cancer target associated with poor prognosis and metastasis in the most common gastrointestinal tumors including Colorectal Cancer, Gastric Cancer, and Neuroendocrine Tumours. The clinical program for CHM CDH17 builds upon the preclinical studies published in the preeminent scientific journal, Nature Cancer in March 2022. Chimeric Therapeutics aims to bring the promise of cell therapy to life for more patients with cancer and is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.